Cargando…
Somatostatin Receptor Theranostics for Refractory Meningiomas
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy. The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 17...
Autores principales: | Salgues, Betty, Graillon, Thomas, Horowitz, Tatiana, Chinot, Olivier, Padovani, Laetitia, Taïeb, David, Guedj, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406720/ https://www.ncbi.nlm.nih.gov/pubmed/36005176 http://dx.doi.org/10.3390/curroncol29080438 |
Ejemplares similares
-
Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with (68)Ga-DOTATOC PET/CT
por: Horowitz, Tatiana, et al.
Publicado: (2023) -
Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature
por: Filippi, Luca, et al.
Publicado: (2022) -
Somatostatin Receptors in Human Meningiomas—Clinicopathological Aspects
por: Tollefsen, Sofie Eline, et al.
Publicado: (2021) -
Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
por: Wu, Wei, et al.
Publicado: (2020) -
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
por: Graillon, Thomas, et al.
Publicado: (2017)